38412 Federal Register / Vol. 87, No. 123 / Tuesday, June 28, 2022 / Notices 

health insurance issuers offering group 

or individual health insurance coverage 

to annually report to the Department of 

the Treasury, the Department of Labor 

(DOL), and the Department of Health 

and Human Services (HHS) 

(collectively, ‘‘the Departments’’) certain 

information about prescription drug and 

health care spending, premiums, and 

enrollment under the plan or coverage. 

This information will support the 

development of public reports that will 

be published by the Departments on 

prescription drug reimbursements for 

plans and coverage, prescription drug 

pricing trends, and the role of 

prescription drug costs in contributing 

to premium increases or decreases 

under the plans or coverage. The 2021 

interim final rules, ‘‘Prescription Drug 

and Health Care Spending’’ issued by 

the Departments and the Office of 

Personnel Management (OPM) 

implement the provisions of section 

9825 of the Code, section 725 of ERISA, 

and section 2799A–10 of the PHS Act, 

as enacted by section 204 of Title II of 

Division BB of the CAA. OPM joined the 

Departments in issuing the 2021 interim 

final rules, requiring Federal Employees 

Health Benefits (FEHB) carriers to report 

information about prescription drug and 

health care spending, premiums, and 

plan enrollment in the same manner as 

a group health plan or health insurance 

issuer offering group or individual 

health insurance coverage. Form 

Number: CMS–10788 (OMB control 

number: 0938–1405); Frequency: 

Annual; Affected Public: Private Sector; 

Number of Respondents: 356; Total 

Annual Responses: 356; Total Annual 

Hours: 1,684,080. (For policy questions 

regarding this collection, contact 

Christina Whitefield at 301–492–4172.) 

Dated: June 23, 2022. 

William N. Parham, III, 

Director, Paperwork Reduction Staff, Office 

of Strategic Operations and Regulatory 

Affairs. 

[FR Doc. 2022–13769 Filed 6–27–22; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Community Living 

Administration on Disabilities, The 

President’s Committee for People with 

Intellectual Disabilities 

AGENCY: Administration for Community 

Living, HHS. 

ACTION: Notice. 

SUMMARY: The President’s Committee 

for People with Intellectual Disabilities 

(PCPID) will host a virtual meeting for 

its members to identify emerging topics 

to examine in the Committee’s Report to 

the President. All the PCPID meetings, 

in any format, are open to the public. 

This virtual meeting will be conducted 

in a presentation and discussion format. 

DATES: Thursday, July 28, 2022 from 

12:00 p.m. to 4:00 p.m. (EST). 

AGENDA: The Committee will discuss 

survey responses, collectively discuss 

emerging issues facing people with 

intellectual disabilities, and the 

preparation of the PCPID Report to the 

President, including its proposed 

content and format, and related data 

collection and analysis required to 

complete the writing of the Report. 

ADDITIONAL INFORMATION: For further 

information, please contact Mr. David 

Jones, Director, Office of Intellectual 

Developmental Disabilities, 330 C Street 

SW, Switzer Building, Room 1126, 

Washington, DC 20201. Telephone: 

202–795–7367. Fax: 202–795–7334. 

Email: David.Jones@acl.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

Stakeholder input is very important to 

the PCPID. Comments and suggestions 

especially from people with intellectual 

and developmental disabilities, are 

welcomed. If there are comments or 

feedback you would like to share with 

the PCPID as it begins to prioritize its 

work, please share them through the 

following ACL.gov link: https://acl.gov/ 

form/pcpid?j=1555178&sfmc_sub=

191090082&l=6707_HTML&u=

34777761&mid=515008575&jb=0. 

Comments received by June 30, 2022 

will be shared with the PCPID at the 

July 28th meeting. Comments received 

after June 30, 2022 will be compiled and 

shared with the PCPID quarterly. 

Webinar/Conference Call: The virtual 

meeting is scheduled for Thursday, July 

28, 2022 from 12:00 p.m. to 4:00 p.m. 

(EST) and may end early if discussions 

are finished. The meeting will be held 

through a zoom meeting platform. In 

order to participate, you must register in 

advanced of the meeting at the 

following link: https://

www.zoomgov.com/meeting/register/

vJIsdeCpqzgsEiNHISQhI6VBwpr

CzIlu8BU. 

BACKGROUND INFORMATION ON THE

COMMITTEE: The PCPID acts in an 

advisory capacity to the President and 

the Secretary of Health and Human 

Services on a broad range of topics 

relating to programs, services and 

support for individuals with intellectual 

disabilities. The PCPID Charter 

stipulates that the Committee shall: (1) 

provide such advice concerning 

intellectual disabilities as the President 

or the Secretary of Health and Human 

Services may request; and (2) provide 

advice to the President and the 

Secretary of Health and Human Services 

to promote full participation of people 

with intellectual disabilities in their 

communities, such as: (A) expanding 

educational opportunities; (B) 

promoting housing opportunities; (C) 

expanding opportunities for competitive 

integrated employment; (D) improving 

accessible transportation options; (E) 

protecting rights and preventing abuse; 

and (F) increasing access to assistive 

and universally designed technologies; 

and (3) provide advice to the President 

and the Secretary of Health and Human 

Services to help advance racial equity 

and support for people with intellectual 

disabilities within underserved 

communities. 

Dated: June 22, 2022. 

Jill Jacobs, 

Commissioner, Administration on 

Disabilities. 

[FR Doc. 2022–13699 Filed 6–27–22; 8:45 am] 

BILLING CODE 4154–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2020–D–1496] 

Renal Cell Carcinoma: Developing 

Drugs and Biologics for Adjuvant 

Treatment; Guidance for Industry; 

Availability 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of availability. 

SUMMARY: The Food and Drug 

Administration (FDA or Agency) is 

announcing the availability of a final 

guidance for industry entitled ‘‘Renal 

Cell Carcinoma: Developing Drugs and 

Biologics for Adjuvant Treatment.’’ This 

guidance is intended to facilitate the 

development of drugs and biologics for 

the adjuvant treatment of renal cell 

carcinoma and provides 

recommendations for the sponsor on 

this topic. The guidance includes 

recommendations regarding eligibility 

criteria, choice of comparator, followup 

imaging assessments, determination of 

disease recurrence, analyses of diseasefree survival, and interpretation of trial 

results. This guidance finalizes the draft 

guidance of the same title issued on 

October 2, 2020. 

DATES: The announcement of the 

guidance is published in the Federal 

Register on June 28, 2022. 

ADDRESSES: You may submit either 

electronic or written comments on 


khammond on DSKJM1Z7X2PROD with NOTICES